LN 145

Drug Profile

LN 145

Alternative Names: Autologous tumour infiltrating lymphocytes - Iovance Biotherapeutics; LN-145

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA); National Institutes of Health (USA)
  • Developer Iovance Biotherapeutics
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer; Head and neck cancer

Most Recent Events

  • 31 Oct 2017 Iovance Biotherapeutics receives approval for a clinical trial application for initiation of a phase II trial for Cervical cancer in United Kingdom
  • 31 Oct 2017 Iovance Biotherapeutics plans phase II trials for Cervical cancer in Europe
  • 13 Sep 2017 Iovance Biotherapeutics receives approval for clinical trial application for initiation of a phase II trial for Cervical cancer (Recurrent, Metastatic disease) in Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top